Objective-Obesity-induced inflammation in white adipose tissue, characterized by increased macrophage infiltration and associated with macrophage population shift from anti-inflammatory M2 to proinflammatory M1 macrophages, largely contributes to obesity-induced insulin resistance and influences type 2 diabetes mellitus pathogenesis. GSK3 (glycogen synthase kinase 3), a serine/threonine kinase, has been reported to participate in various cellular processes. We sought to examine the potential mechanism by which GSK3, a serine/threonine kinase implicated in various cellular processes, modulates obesity-induced visceral adipose tissue (VAT) inflammation. Approach and Results-Male C57BL/6J mice were fed a high-fat diet for 10 weeks while being treated with vehicle control or GSK3 inhibitors SB216763 or CHIR99021. RNA-sequencing results using VAT demonstrated that GSK3 inhibitor treatment reversed obesity-specific expression of genes associated with inflammation. Consistently, GSK3 inhibition reduced obesity-induced VAT inflammation as characterized by decreased proinflammatory M1 macrophages but increased anti-inflammatory M2 macrophages in the VAT and reduced circulatory inflammatory monocytes. These antiinflammatory effects of GSK3 inhibition were found to be driven, at least in part, by inhibiting production of apoptosis inhibitor of macrophage in macrophages via inactivating STAT3 to reduce free fatty acid and chemokine level produced from VAT to suppress the migration/chemotaxis of macrophages and monocytes. Conclusions-Our findings suggest that GSK3 may act as an important regulator of obesity-induced inflammation and characterize the novel role of GSK3 in shifting macrophage polarization and reinforce its therapeutic potential for obesity-induced inflammation and its associated diabetes mellitus. Visual Overview-An online visual overview is available for this article.
O besity-induced insulin resistance is tightly associated with increased inflammation in obese white adipose tissue (WAT) as indicated by increased infiltration of multiple types of proinflammatory immune cells into WAT. [1] [2] [3] Among these cell types, the macrophage is the first type of immune cells identified and plays a crucial role in obesity-induced insulin resistance and type 2 diabetes mellitus (T2DM). 4 Macrophages can be subdivided into classically activated macrophages (M1), which is F4/80 + MGL1
− and proinflammatory, and alternatively activated macrophages (M2), which is F4/80 + MGL1
+ and anti-inflammatory. 5 Adipose tissue macrophages (ATMs) in obese state are enriched for M1-like macrophages that impair insulin signaling and secrete proinflammatory cytokines, such as TNF α(tumor necrosis factor α), IL (interleukin) 1β, and IL6, while M2 macrophages that produce anti-inflammatory cytokines, such as IL10, are decreased, indicating a shift in the inflammatory profile of ATMs from M2 to M1 macrophages in obese WAT. 3, 6, 7 However, how obesity stimulates infiltration and activation of proinflammatory cells, most importantly of inflammatory macrophages and the transition of M2-to-M1 transition, are largely unknown.
It has been suggested that hypertrophy of adipocytes in obese WAT releases specific small molecules, including saturated free fatty acid (FFA) to activate inflammation-associated signaling pathways in neighboring macrophage. 8, 9 This interaction between adipocytes and macrophages has been hypothesized to contribute to the establishment and aggravation of the chronic inflammation in obese WAT and further supported with the emerging evidence. 10 One of the recently reported molecules that mediate the crosstalk between adipocytes and macrophages is apoptosis inhibitor of macrophage (AIM)/CD5L. Obesity-increased blood AIM induces lipolysis of obese adipose tissue and provokes an efflux of saturated FFA to stimulate TLR-4 (toll-like receptor) pathway, which triggers production of proinflammatory chemokines from adipocytes such as MCP-1 (monocyte chemotactic protein-1) to induce M1 macrophage/monocyte recruitment into adipose tissue and ultimately leads to inflammation in obese WAT and insulin resistance. [11] [12] [13] Thus, blockage of the crosstalk between adipocytes and macrophages through targeting AIM may act as an effective strategy to attenuate obesity-induced inflammation and its associated insulin resistance.
GSK3 (glycogen synthase kinase 3), a serine/threonine kinase, was originally identified for its ability to phosphorylate and inhibit glycogen synthase (GS), 14 which links GSK3, especially GSK3β tightly to insulin signaling pathway as indicated by the evidence that specific overexpression of GSK3β•decreases glucose tolerance and insulin action while knockout of GSK3β or GSK3 inhibition showed opposite effects. [15] [16] [17] [18] [19] [20] [21] Emerging evidence further suggests an association of GSK3 with versatile biological functions, including cell proliferation, differentiation, angiogenesis, and energy metabolism, beyond its known effect on GS activity. The association of GSK3 and inflammation was also reported. 22 The administration of GSK3 inhibitors to rodent models with obesity and diabetes mellitus contributes to improved insulin sensitivity and glucose metabolism. 20, 21, [23] [24] [25] These studies suggest the important effect of GSK3 in energy metabolism and insulin signaling and indicate a promising therapeutic strategy to target GSK3 in insulin resistance and diabetes mellitus treatment. However, some findings suggest that GSK3 may regulate glucose metabolism and mediate insulin resistance development independent of the effect on glycogen synthesis. 26 Particularly, GSK3β activity was found higher in adipose tissue of obese diabetic mice, 27 but the detailed mechanism by which GSK3 functions in adipose tissue to influence the development of obesity and its associate metabolic disorders such as insulin resistance remains open for investigation. As the important regulatory organ of energy metabolism, adipose tissue plays an importantly role in obesity-induced insulin resistance and diabetes mellitus through secreting inflammatory cytokines and chemokines. The examination of GSK3 function in the obese adipose tissue biology will contribute to reveal the pathogenesis of obesity and its associated disorders and enable the therapeutic potential of targeting GSK3 in the treatment of obesity-associated T2DM to be more thoroughly assessed.
In the present study, we proposed a hypothesis that GSK3 may contribute to the obesity-induced inflammation through regulating macrophage infiltration to adipose tissue. Our results confirm that GSK3 inhibition reverses obesity-induced inflammation in adipose tissue via reducing AIM level to attenuate macrophage/monocyte migration. In addition, we determined the molecular mechanism by which GSK3 activates STAT3 to promote its transcriptional activity on AIM gene. Our findings identify a novel role of GSK3 in regulating macrophage recruitment and infiltration during obesity.
Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Animal Studies
Wild type male C57BL/6 mice were obtained from the Animal Facility of the Faculty of Health Sciences of University of Macau. The reason we used male mice for our study is that some reports suggested that although male and female C57Bl/6 mice both gain weight when exposed to a high-fat diet such as the diet with 60 kcal% fat, the obese males developed more weight gains than female mice. 28 And only male mice fed with a high-fat diet such as the diet with 60 kcal% fat that is the diet we used in our study were insulin resistant and glucose intolerant and developed adipose tissue inflammation. 29 In addition, other reports suggested that the effect of estrogen on inflammation is contradictory. 30 Based on above reasons, we used male mice as our mice model. The mice were maintained under a 12-hour light/dark cycle with free access to food and drinking water. Mice were fed control diet (10 kcal% fat) or high-fat diet containing 60 kcal% fat (D12491, Research Diets Inc, New Brunswick, NJ) to induce high-fat diet induced obese (DIO) starting at 6 weeks of age for 10 weeks. SB216763 treatment (10 mg/kg) and CHIR99021 (10 mg/kg; dissolved in 10% dimethyl sulfoxide in PBS) were used for intraperitoneal injection, and the control group was injected with 10% dimethyl sulfoxide in PBS as vehicle control. IL15 (0.5 mg/ mouse) was administered by subcutaneous injection, and saline was used as a control (every 2 days for last 4 weeks at indicated doses). Insulin tolerance tests were performed as described. 31 All animal protocols were conducted under the University of Macau guidelines and approved by the University's Animal Ethics Committee.
Cell Culture and Macrophage-Conditioned Media
Mouse 3T3-L1 preadipocytes (ATCC) were cultured and differentiated as described. 32, 33 RAW264.7 cells were cultured in DMEM with 10% heat-inactivated fetal bovine serum and treated with vehicle, lipopolysaccharides (100 ng/mL), or IL4 (10 ng/mL) together with SB216763 (20 µmol/L) or CHIR99021 (10 µmol/L) for 12 hours. The resultant media were used as conditioned media (CM) for 3T3-L1 adipocyte culture (60% in normal DMEM).
Reagents and Antibodies
Reagents and antibodies include anti-F4/80 (11-4801-85&14-4801-85), anti-Ly6C (17-5932-80), anti-NK1.1 (12-5941-82&14-5941-82), anti-CD3 (11-0032-82), anti-CD4 (12-0041-82), anti-CD8 (17-0083-81), anti-CD25 (17-0251-81), anti-Foxp3 (11-5773-80 
ATM Selection and SVF Cell Extraction
ATM was isolated as previously described. 34 Stromal vascular fraction (SVF) cells were extracted as described. 3 Briefly, visceral adipose tissue (VAT) were digested by collagenase type 2 (Sigma) at 37°C for 40 to 60 minutes. VAT cell suspensions were centrifuged at 500g for 5 minutes to separate floating adipocytes from SVF pellet.
Serum and VAT Lysate Parameter Analysis
Cytokines and chemokines concentration were measured based on the MILLIPLEX Multiplex Assays using the Magpix system using adipose tissue extraction or serum. Plasma concentrations of compounds were examined by liquid chromatography/mass spectrometer (Waters Q-Tof system).
Flow Cytometry and Sorting
SVF of VAT was analyzed by flow cytometry as previously described. 3 Briefly, SVF isolated from adipose tissue samples was resuspended in fluorescence-activated cell sorter buffer, and cells were incubated with fluorophore-conjugated primary antibodies or isotype control antibodies for 50 minutes. The working concentration of antibodies is 5 μg/mL. Macrophage proliferation was assessed using BrdU labeling. BrdU labeling was achieved by supplementing drinking water with 0.8 mg/mL BrdU for 9 consecutive days followed by a changeover to normal water. Adipose macrophages were sorted by separation of F4/80 + (macrophage) and F4/80 − (nonmacrophage) fractions of SVF cells. BD FACSAria III and BD FACSDiva software were used for flow cytometric and sorting analyses.
Macrophage Chemotaxis Assay
The chemotaxis assay was performed using EZCell 96-well Cell Migration/Chemotaxis Assay Kit (BioVision, Inc). Briefly, 1×10 6 cells/ mL per well were seeded in the upper chamber with polycarbonate membrane at the bottom, and respective chemoattractant was added in the lower chamber (see Figure IVE in the Data Supplement for the detailed procedure in our study). After incubation at 37°C for 12 hours, migrated cells were dissociated in Cell Dissociation Solution containing cell dye at 37°C for 60 minutes, and the relative fluorescence unit was analyzed at Ex/Em=530/590 nm in a plate reader.
Cellular Respiration and Extracellular Acidification
XF e 24 Extracellular Flux Analyzer (Seahorse Biosciences) was used to determine the bioenergetic profile of intact cells including oxygen consumption rate (OCR), extracellular acidification rate (ECAR), and fatty acid oxidation. To assess fatty acid oxidation, DMEM media containing 11 mmol/L glucose and 0.5 mmol/L carnitine was used as an assay media, and sodium palmitate was administered at a final concentration of 200 µmol/L. 31 All media included 2 mmol/L l-glutamine. Results were normalized to the actual cell count or protein concentration immediately after OCR and ECAR recordings.
RNA-Sequencing (RNA-Seq) Analysis
Pair-end RNA-seq was performed on Illumina Hiseq 2500 platform in 2 replicates. In total, the reads mapped to reference genome (UCSC mm10) are 39976174/LE1, 41749508/LE2, 36566839/ OB1, 46796012/OB2, 42210891/SB1, and 63636348/SB2. Tophat (v2.0.13) was used for reads mapping, and Cufflinks (v2.2.1) was used for gene and transcript expression levels retrieval. Differentially expressed genes were determined by fold-change in average with 1.5 as the cutoff. The heatmap figures were produced with 2 different R packages-ComplexHeatmap and pheatmap.
Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction (PCR)
The total RNA was extracted from the cells using TRIzol (Invitrogen), and 2 µg was reverse-transcribed in a 40-µL volume system (QuantiTect reverse transcription kit [Qiagen] ) for quantitative PCR assays. Quantitative real-time PCR analyses were performed using gene-specific primers in a QuantStudio 7 Flex Real-Time PCR (Applied Biosystems, Foster City, CA). For relative mRNA quantification of all of the genes, SYBR Green real-time reverse transcription PCR was used with normalization to the mouse housekeeping gene S16 as an internal control. Primer sequences are included in Table I in the Data Supplement.
RNAi
For the knockdown experiments, the sequences of siRNAs (small interfering RNAs) specific for Gsk3b (GAACCGAG AGCTCCAGATC) 35 and the negative control siRNA (AAUUCUC CGAACGUGUCACGU) were used in our study. The oligomers were annealed and inserted into the pLKO.1 lentiviral vector for expression of shRNA (short hairpin RNA).
Western Blotting
The cells were lysed in radioimmune precipitation assay buffer supplemented with protease and phosphatase inhibitors (Sigma-Aldrich). The lysates were resolved with 10% Tris/glycine SDS-PAGE and transferred to nitrocellulose membranes. The working concentrations of antibodies is 0.4 μg/mL from Santa Cruz Biotechnology and 1:1000 dilution from Cell Signaling Technology. Western blot signals were quantified by standard densitometric analysis using NIH ImageJ version 1.47 program.
Histology and Microscopy
Hematoxylin and eosin-stained sections were imaged for crown-like structures. Immunofluorescence was performed for macrophage detection by incubation with directly conjugated primary anti-F4/80 antibodies (5 μg/mL) as previously described. 33 Immunohistochemistry was performed for natural killer (NK) cell marker NK1.1 by incubation with NK1.1 antibody (5 μg/mL). Flow cytometry-sorted macrophages were cytospun to slides. The slides were incubated with Ki67 antibody (1:200 dilution) and fluorescence-conjugated secondary antibody (Santa Cruz Biotechnology). The samples were examined, captured, and quantified under an Axio Observer Z1 inverted microscope (Carl Zeiss MicroImaging).
Statistical Analysis
For 2-group comparisons, if data passed normality and equal variance tests, Student t test was performed, with P<0.05 defined as statistically significant. Otherwise a nonparametric test (such as MannWhitney rank-sum test) was performed. For >2 group comparisons, if data passed normality and equal variance tests, 1-way ANOVA with an Dunnet post hoc test at α=0.05 was used. Otherwise, KruskalWallis 1-way ANOVA on ranks was used.
Results

GSK3 Phosphorylation Decreases in Obese VAT and GSK3 Inhibition Attenuates Obesity-Induced Insulin Resistance Without Affecting Body Weight in DIO Mice
We examined GSK3 expression and phosphorylation in the VAT of lean mice and DIO mice. We observed that the phosphorylation (Ser9) level of GSK3β was strongly decreased in the VAT of DIO mice by the GSK3 inhibitor ( Figure 1A ). Because GSK3β activity is negatively regulated by Ser9 phosphorylation, this suggests an increased GSK3β activity in the VAT of DIO mice. Although a high level of GSK3β was also detected in the liver and skeletal muscle ( Figure 1B ), no remarkable change of GSK3β phosphorylation was observed ( Figure 1B) . We also observed a decreased GSK3β phosphorylation in both obese adipocyte-enriched fraction and importantly, in SVF which contains infiltrated macrophages within VAT and is known to be the main producers of inflammationassociated factors, 36 suggesting an increased activity of GSK3 in these 2 fractions of VAT from DIO mice ( Figure 1C ). β-Catenin protein level also decreased in the obese VAT, adipocytes, and SVF compared with lean control ( Figure 1D ), which is consistent with the inhibitory effect of GSK3 on its downstream target β-catenin.
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To investigate how GSK3 influences diet-induced obesity and its associated insulin resistance, we treated obese mice for last 4 weeks during DIO using GSK3-specific inhibitors SB216763 (SB). We performed dose-response experiment and found that the improved insulin resistance by GSK3 inhibitor was dose dependent with low-dose SB (1 mg/kg, IP) showing minimal improvement and increased dose (5 and 10 mg/kg) showing significant improvement ( Figure 1E ). We chose 10 mg/kg for the subsequent experiments. These GSK3 inhibitor-treated DIO mice also exhibited lower blood and serum glucose ( Figure 1F and 1G). GSK3 inhibition in DIO mice did not change body weight and fat mass compared with vehicle-treated DIO mice ( Figure IA and IB in the Data Supplement), suggesting that the improved insulin resistance is not because of changed body weight.
GSK3 Inhibition Results in Transcriptional Suppression of Inflammation-Related Genes
To further examine the pathophysiological function of GSK3 in obese adipose tissue, we then examined the gene expression profile of VAT from lean-, DIO (obese)-, and SB (SB)-treated DIO mice through high throughput RNA-seq. By comparing to obese VAT, 1187 upregulated and 3837 downregulated genes were identified in lean VAT, and 959 upregulated and 1498 downregulated genes were identified in SB VAT, respectively ( Figure 2A) . By overlapping the differentially expressed genes in lean and SB groups, 412 genes were commonly upregulated and 1126 transcripts were commonly downregulated in both lean and SB compared with obese VAT (Figure 2A ). As shown in the heatmaps ( Figure 2B and 2C) , most of the common differentially expressed genes in lean and SB VAT showed a dramatically differential expression between lean and obese while SB treatment reversed the obese-specific gene expression pattern toward the lean-like gene expression pattern but was not comparable to lean. Gene ontology analysis of the commonly upregulated differentially expressed genes in lean and SB VAT identified several gene ontology terms, including metabolic process, response to insulin, glucose transport, and homeostasis, etc ( Figure 2C ). In contrast, obese VAT-enriched genes are associated with gene ontology terms that include inflammatory response, positive regulation of cytokine secretion, IL6 production, monocyte/macrophage chemotaxis and activation, cellular response to TNF, etc ( Figure 2B ).
By analyzing SB downregulated genes using gene set enrichment assay, the gene functions, such as leukocyte . GSK3 (glycogen synthase kinase 3) activity is increased in visceral adipose tissue (VAT), and GSK3 inhibition improves insulin resistance and glucose tolerance during high-fat diet induced obese. A, Phosphorylated-(Ser9) GSK3β and total (t)-GSK3β in VAT isolated from lean (LE) and diet-induced obese mice (OB) were analyzed by Western blotting and quantified. B, GSK3β phosphorylation level was examined in skeletal muscle, and livers isolated from LE and OB mice were analyzed by Western blotting and quantified. C, Phosphorylated (p)-GSK3β and total (t)-GSK3β in adipocyte-enriched fraction (Adipo) and stromal vascular fraction (SVF) isolated from LE and OB mice were analyzed by Western blotting and quantified. D, β-Catenin protein level was determined in VAT and in adipocyte-enriched and SVF fractions. E, Insulin tolerance test was performed in indicated mice. Fasting blood glucose levels (F) and serum glucose levels (G) were measured in mice with indicated treatment. Bar graphs are mean±SD (n=3-5). Data are representative of 3 independent experiments. *P<0.05; **P<0.01. ***P<0.001. chemotaxis and migration, IFNγ (interferon gamma)-mediated signaling pathway, and regulation of IL6 (a predictor of diabetes mellitus) production, were also found to be among the top hits ( Figure IC-IG Figure 2D ), suggesting GSK3 inhibition may suppress obesity-induced inflammation in VAT. Interestingly, we observed that obesity-induced expression of AIM/Cd5l, a mediator of crosstalk between adipocytes and macrophage, was strongly decreased by GSK3 inhibition, which promotes us to hypothesize that GSK3 inhibition may reverse obesity-induced adipose tissue inflammation through regulating AIM level.
GSK3 Inhibition Decreases Inflammation and Inflammatory Macrophage Accumulation in VAT During DIO
Next, we further assessed whether GSK3 inhibition can really attenuate obesity-induced inflammation in the obese VAT. We chose 2 highly selective GSK3 inhibitors within the low nanomolar concentration range, including SB216763 and CHIR99021, and these 2 compounds inhibit GSK3 in an ATP competitive manner. 37 The application of 2 GSK3 inhibition could exclude the possibility that the caused effects by the single inhibitor are through other unknown off-target effects. Consistent with the RNA-seq data, the repressed expression of macrophage marker genes CD11c, CD68, and F4/80 and the proinflammatory cytokine/chemokine genes such as Tnfa, Il1b, Mcp1 and 3 in obese VAT were further validated by quantitative PCR on SB and CHIR treatment (Figure 3A and 3B; Figure IIA in the Data Supplement). However, we did not observe a significant change of these genes in the liver of DIO mice by SB ( Figure IIB and IIC in the Data Supplement). GSK3 inhibitors treatment also reduced the serum level of TNFα, the important contributor to obesity-induced insulin resistance 38, 39 and increased anti-inflammatory IL10 protein level ( Figure 3C ; Figure IID in the Data Supplement). Hematoxylin and eosin staining of VAT section showed a decreased inflammatory property as indicated by reduced crown-like structures around adipocytes in SB-treated DIO mice ( Figure 3D ). The crown-like structures consist mostly of macrophages. 40 A decreased staining of macrophage marker F4/80, reduced total macrophage percentage (by ≈9.5%), and cell number (by ≈28%) were also observed in the VAT of SB-treated DIO mice ( Figure 3E-3G) , suggesting decreased macrophage infiltration to VAT and inhibited VAT inflammation.
To examine which GSK3 inhibitor is more advantageous, we first examined plasma level of these 2 inhibitors after injection of these 2 inhibitors at the same dose (10 mg/ kg). A higher plasma level of SB compared with CHIR was observed ( Table I in We observed similar effects of CHIR on decreased M1 markers but increased M2 markers ( Figure IIF in the Data Supplement). Correspondingly, GSK3 inhibitors reversed obesity-induced serum level of proinflammatory TNFα, IL1β, and MCP-1 ( Figures 3C and 4E ), whereas serum IL10 was increased ( Figure 3C ; Figure IID in the Data Supplement). The similar effects of both GSK3 inhibitors SB and CHIR support the hypothesis that inhibiting GSK3 activity reverses obesity-induced macrophage phenotypic shift in the VAT to reduce obesity-induced inflammation.
M1 and M2 macrophages rely on glycolysis and oxidative phosphorylation for their energy supply, respectively. We isolated macrophages from SB-treated DIO mice 34 and observed these macrophages showed increased OCR (an indicator of oxidative respiration) but decreased ECAR (an indicator of glycolysis) compared with vehicle-treated macrophages ( Figure 4F and 4G) concomitant with increased fatty acid β-oxidation in SB-treated macrophages ( Figure 4H ). Mitochondrial dysfunction enhances inflammation in VAT. 42 Our above data suggest that GSK3 inhibitor stimulates a beneficial reprogramming of cellular metabolism of macrophage to reduce VAT inflammation.
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GSK3 Inhibition Affects NK Cell Activation to Regulate Obesity-Induced Inflammation in Obese VAT
Based on our above phenotypic effect of GSK3 inhibition on reversed M1 macrophage polarization, it is still unclear what is the underlying mechanisms by which GSK3 inhibition alters obese VAT inflammation. Interestingly, we observed decreased serum level and expression of IFNγ in SVF in GSK3 inhibitor-treated mice ( Figures 2D, 4C , and 4E; Figures IF and IID in the Data Supplement). IFNγ was reported being produced by T-lymphocytes and NK cells infiltrated into obese WAT before macrophage recruitment to promote M1 macrophage polarization during DIO. [43] [44] [45] However, SB treatment did not change the expression of T-cell marker gene CD3 and chemokine gene Sdf1a (stromal cell-derived factor 1a; Figure   IIIA and IIIB in the Data Supplement), and T-cell percentage showed no detectable changes after SB treatment ( Figure IIIC in the Data Supplement), indicating GSK3 inhibitors may not regulate DIO-induced T-cell infiltration in our study. In contrast, WAT-resident NK cell-associated genes Nk1.1, CD11b, and NK cell-activating receptor (Ncr1) required for NK celltriggered insulin resistance and macrophage differentiation during DIO 45 were found decreased by GSK3 inhibitors in the VAT as indicated by RNA-seq and quantitative PCR data (Figure 5A and 5B; Figure IIID in the Data Supplement). Decreased immunostaining of NK cell marker NK1.1 was also observed in SB-treated obese VAT ( Figure 5C ). Although above results suggest that the effects of GSK3 inhibition on inflammation are mediated, at least in part, by inhibiting NK cell activation in obese VAT, further studies are required to uncover the direct regulatory mechanism by which GSK3 contributes to NK cell activation during DIO to facilitate proinflammatory macrophage activation.
GSK3 Inhibition Reduces Obese-Induced Inflammation Through Regulating AIM Expression and Its Mediated Immune Cell Migration
To further reveal underlying mechanism by which GSK3 regulates obesity-induced VAT inflammation, we analyzed RNAseq data and noticed that the expression of AIM (also known as CD5L), a factor required for macrophage infiltration to WAT, 12 was dramatically increased in obese VAT and in isolated macrophages but significantly decreased by GSK3 inhibition (Figures 2D, 5D , and 5E; Figure IVA in the Data Supplement). Consistently, the serum level of AIM was increased in obese mice compared with lean mice, and GSK3 inhibition reduced its serum level ( Figure 5F ). AIM was easily detected in isolated macrophages from VAT and macrophage cell line RAW264.7 but repressed by SB and CHIR (Figure 5E and 5G; Figure IVA and IVB in the Data Supplement) while no detectable expression of AIM was found in purified adipocytes from the VAT and differentiated 3T3-L1 adipocytes ( Figure IVB in the Data Supplement). During activation of RAW264.7 macrophage by lipopolysaccharides/IFNγ which induce macrophage activation, 45, 46 AIM expression was also induced and the treatment of SB and CHIR dramatically reduced AIM level ( Figure 5G ). The similar effects of both GSK3 inhibitors on AIM indicate GSK3 inhibitors regulates AIM expression through inhibiting GSK3 activity rather than through other pathways.
We then analyzed the putative promoter region of AIM gene and found the sequences of AIM promoter comprising between −2968 and −2960 contain a putative STAT3-binding site ( Figure IVC in the Data Supplement), indicating that the STAT3 possibly plays a role in regulating AIM expression by affecting the promoter activity of AIM. Interestingly, we observed that the increased phosphorylation of STAT3 (Tyr705) during macrophage activation and SB treatment inhibited STAT3 phosphorylation ( Figure 5H ). Promoterluciferase reporter gene construct containing this STAT3-binding site was transfected into RAW264.7 macrophages without or with STAT3 expression. Ectopic expression of STAT3 significantly increased luciferase activity of the promoter of AIM gene ( Figure 5I ). Conversely, a mutation in the STAT3-binding site attenuated luciferase activity even with STAT3 overexpression ( Figure 5I ). Importantly, GSK3 inhibition abolished the effect of ectopic expression of STAT3 on luciferase activity ( Figure 5I ). Consistently, STAT3 overexpression in macrophages increased AIM expression ( Figure 5G ). We also observed that increased phosphorylation of STAT3 was reduced by GSK3 inhibition in SVF isolated from obese VAT ( Figure 5J ). These results indicate that GSK3 may activate STAT3, at least in part, to regulate the activity of the promoter of AIM to influence AIM expression.
Macrophage-specific expression of AIM is required for macrophage infiltration to VAT via inducing lipolysis in adipocytes. 12 Thus, we treated macrophages with GSK3 inhibitors or knocked down GSK3β ( Figure IVD in the Data Supplement), which decreased AIM production in macrophages ( Figure 5G ). Collected macrophage culture medium containing AIM was used to culture 3T3-L1 adipocyte to allow AIM to be incorporated into adipocytes. Then CM from 3T3-L1 adipocytes challenged by RAW264.7 macrophage culture medium with or without GSK3 inhibitor stimulation or GSK3β knockdown was used as stimulants to assess migration/chemotaxis ( Figure IVE in the Data Supplement). We observed the CM with decreased AIM caused by GSK3 inhibition or GSK3 knockdown significantly decreased the migration of macrophages, but recombinant AIM addition rescued the migration ( Figure 5K ). We observed similar phenomenon using J774.1 mouse monocyte cells ( Figure IVF in the Data Supplement), suggesting that AIM mediates the effect of GSK3 on macrophage migration and recruitment of macrophages to adipocytes, ultimately leading to changed VAT inflammation.
GSK3 Regulates Chemokine Production via AIM to Mediate Circulatory Monocyte Infiltration to Affect Inflammatory Macrophage Accumulation in Obese VAT
Obesity-induced M1-like macrophage accumulation within WAT results largely from the increased migration of circulating inflammatory Ly6C hi CCR2
+ (C-C chemokine receptor type 2) monocytes to WAT, which requires some chemokines such as a CCL2 (C-C motif chemokine ligand 2)/CCR2-dependent macrophage recruitment to adipocytes has been reported. 3, 6, 47 We then analyzed AIM effect on chemokine production in adipocytes. Comparison of the effect of CM of macrophage without or with GSK3 inhibition on chemokine expression in 3T3-L1 adipocytes showed GSK3 inhibition decreased CM-stimulated chemokine expression while recombinant AIM recovered the response of adipocytes to CM ( Figure 6A ). These data promote us to conclude that the effect of GSK3 on AIM in macrophage may modulate chemokine level produced in adipocytes to regulate immune cell recruitment from circulation.
The AIM-mediated interaction between adipocytes and macrophages augments obesity-induced inflammation through increased FFA released from adipocytes and increased chemokines.
12,13 Interestingly, we observed that obesity-increased serum AIM level was decreased by GSK3 inhibitor treatment ( Figure 6B) . Similarly, macrophage CM-stimulated FFA released by 3T3-L1 adipocytes was suppressed by GSK3 inhibitor-treated macrophages CM, and recombinant AIM reversed this reduction ( Figure 6C ). Our RNA-seq data also confirmed GSK3 inhibition downregulated cell chemotaxis and migration-associated genes, including Ccl2 and Ccr2 (Figure 2B Figure 6D ). CHIR also exhibited a similar effect on the expression of Ccl2 and Ccr2 ( Figure IIA in the Data Supplement), suggesting these effects are mediated through GSK3 inhibition rather than through off-target effects of GSK3 inhibitors, and the protein level of CCL2 in VAT and serum was also decreased by GSK3 inhibition (Figure 6E and 6F) . We then predicted that decreased FFA and chemokines caused by GSK3 inhibition downregulated AIM may decrease M1-like Figure 6G and 6H), suggesting that GSK3 inhibition blocks circulatory immune cell migration to adipose tissue through repressing AIM-simulated FFA release and chemokine production, which ultimately leads to decreased macrophage accumulation in obese VAT.
IL4, the cytokine that promotes M2 macrophage selfgenerate via increasing its proliferation, was increased by SB treatment in VAT and serum ( Figure 6I ). Ki67 staining and BrdU uptake analysis of MGL1 − and MGL1 + macrophage subset demonstrated that SB promoted MGL1 + population (M2 macrophages) proliferation as indicated by increased Ki67 staining and BrdU uptake ( Figure 6J-6L) . A recent report that IL1 could negatively regulate IL4 expression 48 together with our data that GSK3 inhibition reduced IL1 expression (Figures 2 and 3) indicate that GSK3 inhibition may stimulate M2 macrophage proliferation through increasing IL4.
Discussion
Here, we report that GSK3 regulates activity of STAT3 to modulate the expression of AIM, a contributor to immune cell chemotaxis and increased by IFNγ produced from GSK3-activated NK cell during obesity, to collectively promote obesity-induced M1 macrophage polarization within VAT, which ultimately leads to increased VAT inflammation and insulin resistance ( Figure 6M) .
As an important kinase identified several decades ago, GSK3 is known to be associated with a variety of signaling pathways beyond its classical role in phosphorylating GS and therefore involved in many different biological functions and human diseases and emerged as an important target for drug development for various diseases. 32, 33, 49, 50 GSK3 is broadly expressed in most of the tissues, and recent evidence starts to address an important role of GSK3 in regulating insulin sensitivity in multiple types of tissues. GSK3 activities in liver, skeletal muscle, and pancreas have been found to be positively associated with insulin resistance and T2DM in obese and diabetic humans and rodents. [17] [18] [19] 51 It is now under development to use GSK3 inhibitors as new promising drugs for T2DM and other diseases with elevated GSK3 activity, such as neurodegeneration and inflammation. 52 Considering the important role of obese adipose tissue and its induced inflammation in the development of insulin resistance and diabetes mellitus, it is of great importance to investigate whether GSK3 could affect obesity-induced inflammation to provide more insights into the development of therapeutic strategy targeting GSK3. Our data that GSK3 inhibitors ameliorated DIO-induced insulin resistance and importantly, GSK3 inhibitors significantly reduced obesity-induced inflammation and macrophage infiltration in the VAT in DIO mice highlight the therapeutic potential of GSK3 inhibitors in the treatment of obesity-induced inflammation-associated diseases, such as T2DM. Mechanistically, our findings demonstrate that GSK3 inhibition regulates obesity-induced adipose tissue inflammation through reversing obesity-induced macrophage phenotypic switch from M2 polarization state to M1 polarization state and indicate that GSK3 activity contributes to the recruitment of a macrophage population phenotypically similar to that observed during DIO. GSK3-regulated adipose tissue inflammation was found to be mediated by AIM, a factor required for the recruitment of macrophages into obese WAT 12 through regulating macrophage activation and migration and affecting circulating inflammatory Ly6C hi CCR2
+ monocyte recruitment to obese adipose tissue. Furthermore, GSK3-regulated AIM expression is mediated by activated STAT3 that binds to AIM promoter to regulate its expression. It is well-known that GSK3 affects insulin resistance through directly regulating GS activity, especially in skeletal muscle. However, emerging studies demonstrated numerous GSK3 targets in both rodents and human, which promote us to investigate whether other factors could also mediate GSK3 effect in obese adipose tissue to affect obesity-induced inflammation and its associated insulin resistance. Our in vitro and in vivo data indicate that GSK3 may contribute to obesityinduced inflammation through GSK3/STAT3/AIM axis to regulate inflammation-associated cytokine and chemokine production and modulate obesity-induced ATM accumulation and inflammation to ultimately affect obesity-induced insulin resistance, which provides some evidence that the GSK3 may contribute to insulin resistance through regulating other pathways beyond its effect on GS activity. Information is limited on the initial events that promote obesity-induced inflammation in WAT. Infiltration of CD3 + / CD4 − /CD8 − T-cells into obese WAT was reported to be an early event during DIO before macrophage infiltration. 43, 44, 53 However, we did not observe the effect of GSK3 inhibitors on T-cell including the expression of T-cell marker gene CD3 and SDF1α and T-cell percentage in the obese VAT, suggesting GSK3 inhibitors may not modify obesity-caused T-cell infiltration into the VAT. Recently, it was reported that NK cells are both required and sufficient to promote obesityinduced M1 macrophage accumulation, inflammation, and insulin resistance via secreting IFNγ in obese WAT independent of adaptive immune system. 45, 54 We demonstrated that GSK3 inhibitors suppressed obesity-induced NK cell activation and IFNγ expression. Of note, AIM was found to inhibit NK cell apoptosis. 55 Thus, whether the decreased AIM is critical or contributes, at least in part, to the inactivation of NK cells as we observed in GSK3 inhibited condition deserves further investigation. A probable working mechanism, by taking AIM into consideration, is that GSK3 inhibitors initially restrain obesity-induced NK cell activation and IFNγ production, which in turn prevents the accumulation of proinflammatory macrophages in the VAT and works together with decreased AIM production in macrophages to reduce VAT inflammation.
Our study provides a good understanding of the detailed molecular mechanism by which GSK3 inhibitors affect biological and pathological functions of multiple tissues and adds data to the discussion for the development of treatment of inflammation-associated T2DM with GSK3 inhibitors. Supporting the observations in our and other published animal models, plenty of studies demonstrated that small cell-permeable inhibitors of GSK3β can regulate glucose metabolism and insulin action. 18, 20, [56] [57] [58] The administration of GSK3 inhibitors to rodent models with obesity and diabetes mellitus contributes to improved insulin sensitivity and glucose metabolism. 20, 21, [23] [24] [25] Cumulative evidence also suggests a promising therapeutic potential of GSK3 inhibitors for the treatment of a wide variety of other diseases in addition to diabetes mellitus. For example, some preclinical or clinical trials at different phases for Alzheimer disease prevention, neuroprotection, antidepressants, or antiobesity have been conducted using some pharmacological molecules used to study the biological and pathological roles of GSK3, such as NP031112, lithium, and SB216763. 37 However, considering GSK3 also plays critical roles in various key biological processes, some concerns have also been raised and therefore treatment using GSK3 inhibitors could be challenging owing to the adverse side effects caused by other unknown off-target activity of GSK3 inhibitors or other potential toxicity. For example, the lithium had been found to be toxic in some elderly patients, and studies with lithium were thus discontinued. 59, 60 Therefore, it would be extremely critical to develop GSK3 inhibitors with high selectivity targeting individual pathway. As the highly selective GSK3 inhibitors within the low nanomolar concentration range SBs including SB-216763 and CHIRs including CHIR99021 have been demonstrated to enhance self-renewal of ES cells, reduce neuronal death and tau phosphorylation, show therapeutic benefit in Alzheimer disease and diabetes mellitus in rodent models although some discrepant studies were reported. 21, 37, 52 Nevertheless, an overinhibition may, at least in part, account for these discrepancies, suggesting a proper inhibition of GSK3 to physiological activity under pathological conditions associated with an elevated GSK3 activity such as in diabetes mellitus would be crucial to produce a therapeutic effect without producing adverse effects.
In conclusion, our findings demonstrate the involvement of GSK3 inhibition in the reversal of obesity-induced VAT inflammation and suppression of macrophage infiltration into VAT via regulating NK cell activation and reducing AIM production in macrophages to block macrophage recruitment to the VAT. Our findings characterize a novel function of GSK3 in obesity-induced VAT inflammation in prediabetic condition, thus providing further evidence for the potential of GSK3 as a therapeutic target for inhibition of obesity-induced inflammation and its associated insulin resistance.
